Clinical Trials Browser

Phase 2 × Neoplasms by Histologic Type × penpulimab × Clear all

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Phase 2 Unknown

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse